That is the title of a paper published today in Future Oncology with co-authors Erin Mulvey, Kyi-Sin Than, Sanjana Muthukrishnan, Alex Mutebi, Anindit Chhibber, Anthony Wang, Abualbishr Alshreef, Diala Harb, Victor Gonzalez,.
Joel Mokyr, Philippe Aghion and Peter Howitt. The Nobel Prize committee said that the award was merited “for having identified the prerequisites for sustained growth through technological progress”
The Nobel Prize.
…is large. At least according to a recent paper by Graham and Mujcic (2025). The focus of the paper is on the on the long term.
That is the title of my guest column at The Evidence Base. An excerpt is below:
Multiple indicators suggest that health economics and outcomes research (HEOR) faces.
Last month, the American Heart Association (AHA) and American College of Cardiology (ACA) put out a statement on how new cardiovascular medical technologies should be evaluated from a cost and value standpoint.
That is the title of a recent paper by Gao, Kim, and Sevilir (2025). The authors examine 1218 hospital merger and acquisition (M&A) deals in the hospital industry between 2001 and.
Should health technology assessment (HTA) processes consider using distributional cost effectiveness analysis (DCEA) to incorporate technology impacts on inequality? Some say ‘yes’ and some say ‘no’. Let’s take a look at.
Many policymakers aim to reduce health disparities across groups. In fact, the distributional cost effectiveness analysis (DCEA) approach aims to incorporate treatment value based on the extent to which they reduce.
